The prognostic value of BCL-2 expression, solely and combined with Ki-67 expression, was determined in prostate cancer patients followed expectantly. Furthermore, associations with well established prognostic markers were tested. Formalin ®xed, paraf®n-embedded tumour tissue obtained at diagnosis was immunohistochemically investigated in 221 patients with a 15 y median followup time. BCL-2 protein was expressed in 114 (52%) tumours and was signi®cantly associated with tumour stage (P 0.01). The prognostic value of BCL-2 expression was signi®cant, using both disease-speci®c (P 0.0015) and overall survival (P 0.005) as endpoint. Patients with a combined BCL-2 negative/Ki-67`low' tumour had the most favourable prognosis. This combined BCL-2/Ki-67 variable was of independently prognostic value in both the entire population (P 0.0001) and in the clinically localized subpopulation (P 0.035).

ErratumIn the paper``Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly'' by M Borre et al., Prostate Cancer and Prostatic Disease (1998), 1, 268±275, Table 3 was incorrect, the correct version is shown below.

ErratumIn the paper``Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly'' by M Borre et al., Prostate Cancer and Prostatic Disease (1998), 1, 268±275, Table 3 was incorrect, the correct version is shown below. RR: relative risk. Cnf.l: con®dence limit. a (T1a vs T1b vs T2 vs T b 2). b (well vs moderate vs poor).